Mineralys Therapeutics, Inc. (MLYS)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$28.21-0.21%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · MLYS
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
A comparable price-assumption read is not available for this company.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Elevated risk of a next-quarter earnings miss: this name has erratic recent earnings surprises and operates in a high-miss-rate industry. A fundamental tilt, not a price call.
Model as of 2026-09-04 · Compared with 398 industry peers · Company calendar date is not available
MLYS — credit agreement
Dated 2026-06-03
Entry into a Material Definitive Agreement. Fourth Amendment to the License Agreement On June 2, 2026, Mineralys Therapeutics, Inc. (the “Company”) entered into a fourth amendment (the “Amendment”) to that certain License Agreement, dated July 9, 2020 and amended on November 24, 2020, June 15, 2023 and May 29, 2025 (the “License Agreement”), between the Company and Tanabe Pharma Corporation (“Tanabe”) for the purposes of terminating the Company’s potential future royalty payments to Tanabe an…
Why it matters: Finalizing this agreement could stop future royalty payments. This would help cash flow.
Supportive ifAn announcement will confirm the deal is done with Tanabe.
Worry ifMore delays or problems in reaching the agreement with Tanabe.
Why it matters: Good launch plans show they are ready to use lorundrostat's approval. This affects future earnings.
Supportive ifManagement says launch plans are on track for the next quarterly update.
Worry ifManagement says there are delays or problems with the launch plans.
Why it matters: Finalizing this deal will help lorundrostat make more money. It will also lower future royalty costs.
Supportive ifMineralys says the deal with Tanabe Pharma is done.
Worry ifMineralys does not finalize the deal or has delays.
Why it matters: Updates on cash will show if the company can fund operations into 2028. This is key for ongoing projects.
Watch forCash and equivalents are over $600 million.
Also watch forCash and equivalents are under $600 million.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$141 on $10,000 · ±1.4% | How much price usually moves either way. |
| Bad day | $563 loss on $10,000 · 5.6% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $5,246 loss on $10,000 · 52.5% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: The launch is key to generating revenue and proving the product's market potential.
Supportive ifA press release confirming the successful launch of lorundrostat in the market.
Worry ifNo launch news or delays past the expected timeline.
Why it matters: The FDA's approval will determine if lorundrostat can be launched. This is crucial for the company's future revenue.
Supportive ifThe FDA approves lorundrostat for high blood pressure before the PDUFA date.
Worry ifFDA delays or rejects the NDA for lorundrostat.
Why it matters: Earnings results will show if the company meets expectations. It will also show how it controls costs.
Watch forEarnings per share were higher than analysts expected for Q2 2026.
Also watch forEarnings per share were lower than analysts expected for Q2 2026.
Why it matters: Good launch preparations are key for gaining market share in hypertension treatment. Progress shows readiness for market entry.
Supportive ifManagement says launch preparations are on track and the sales team is ready.
Worry ifManagement reports delays or issues in launch plans.